Belvedere Trading’s Ginkgo Bioworks DNA Stock Holding History

Belvedere Trading’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800	Closed	-$168	–	808
2025 Q4	$168	Hold	800	–	–	﹤0.01%	847
2025 Q3	$272	Hold	800	–	–	﹤0.01%	879
2025 Q2	$216	Buy	800 +300	+60%	+$2.32K	﹤0.01%	796
2025 Q1	$80	Buy	+500	New	+$5.09K	﹤0.01%	672
2023 Q1	–	Sell	-70	Closed	-$4.73K	–	1056
2022 Q4	$4.73K	Buy	+70	New	+$6.44K	﹤0.01%	988
2022 Q2	–	Sell	-255	Closed	-$39K	–	413
2022 Q1	$39K	Sell	255 -660	-72%	-$128K	﹤0.01%	394
2021 Q4	$193K	Buy	915 +97	+12%	+$46.1K	0.01%	212
2021 Q3	$403K	Buy	+818	New	+$398K	0.01%	135

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's DNA Position: Q1 2026 in Review

Belvedere Trading sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 177 shares — an estimated $1.47K sold.

Belvedere Trading first reported a position in DNA in Q3 2021 and held it in 3 quarters. The position peaked at $343K in Q3 2021. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Belvedere Trading reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
Belvedere Trading sold 177 Ginkgo Bioworks shares in Q1 2026, an estimated $1.47K.
Belvedere Trading first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 3 quarters.
Belvedere Trading's Ginkgo Bioworks position peaked at $343K in Q3 2021.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.